Dynavax (DVAX) Price & Analysis

Compare

2,443 Followers

DVAX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$9.22 - $14.63

Previous CloseN/A

Volume272.71K

Average Volume (3M)1.38M

Market Cap

$1.34B

Enterprise Value$1.25B

Total Cash (Recent Filing)$661.34M

Total Debt (Recent Filing)$286.03M

Price to Earnings (P/E)64.5

Beta0.29

Next Earnings

Oct 30, 2025

EPS Estimate

0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.14

Shares Outstanding120,080,650

10 Day Avg. Volume1,012,554

30 Day Avg. Volume1,383,648

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.93

Enterprise Value/Revenue4.24

Enterprise Value/Gross Profit5.15

Enterprise Value/Ebitda-22.96

Forecast

1Y Price Target

$31.00

Price Target Upside178.28% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Growth PotentialDynavax shares are undervalued based on the growth and long-term opportunity of Heplisav, with positive developments from the company’s pipeline supporting additional upside.

Market ShareHeplisav has continued to gain and maintain market share, with an estimated share of the U.S. HBV market increasing to ~43% in Q1.

Medicare AccessExpanded access of Heplisav to Medicare patients and inclusion in HEDIS measures should accelerate growth.

Bears Say

Sales Estimate MissYear-over-year market share gains and revenue growth of 36% are still encouraging despite a slight miss on sales estimates.

Sales PerformanceFirst-quarter Heplisav sales came in below estimates, reflecting a miss on expectations.

Dynavax News

Dynavax reports Q2 EPS 14c vs. 8c last year

Reports Q2 revenue $95.4M, consensus $86.66M. “In Q2 2025, we continued our momentum by delivering robust Q2 results,...

8h ago

DVAX

Dynavax raises 2025 Heplisav-B net product revenue view to $315M-$325M

Previous guidance was $305M-$325M. Consensus for 2025 revenue is $330.56M. Sees 2025 adjusted EBITDA at least $75M. Published...

8h ago

DVAX

Dynavax: Strong Heplisav Sales and Promising Vaccine Pipeline Justify Buy Rating

In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on Dynavax, with a...

2h ago

DVAX

Dynavax Technologies (DVAX) Q2 Earnings Cheat Sheet

Dynavax Technologies (DVAX) is scheduled to report 2nd quarter earnings on 07/31/2025. Regarding Q2 estimates, Wall Street analysts...

10d ago

DVAX

Dynavax Elects Directors and Approves Key Amendments

Dynavax ( ($DVAX) ) has shared an update. On April 14, 2025, Dynavax held its Annual Meeting where...

2M ago

DVAX

Dynavax stockholders elect all director nominees at Annual Meeting

Dynavax (DVAX) Technologies announced that, based on the preliminary vote count provided by its proxy solicitor following the...

2M ago

DVAX

Dynavax urges stockholders vote ‘FOR’ director nominees

Dynavax (DVAX) Technologies Corporation issued the following statement reiterating to stockholders its recommendation to vote “FOR” all four...

2M ago

DVAX

Dynavax shareholder announces Glass Lewis recommendation for board change

Deep Track Capital, with ownership of approximately 14.82% of the company’s outstanding shares, announced that independent proxy advisory...

2M ago

DVAX

Dynavax Appoints New Chief Accounting Officer

Dynavax ( ($DVAX) ) has issued an announcement. On May 8, 2025, Dynavax Technologies Corporation announced the appointment...

3M ago

DVAX

Dynavax Technologies’ Earnings Call: Record Growth Amid Challenges

Dynavax Technologies (($DVAX)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

DVAX

Dynavax urges shareholders to vote for director nominees on Gold proxy card

Dynavax (DVAX) mailed a letter to its stockholders in connection with its 2025 Annual Meeting of Stockholders urging...

3M ago

DVAX

Dynavax price target lowered to $31 from $33 at Citizens JMP

Citizens JMP analyst Jason Butler lowered the firm’s price target on Dynavax (DVAX) to $31 from $33 and...

3M ago

DVAX

Dynavax’s Strategic Positioning and Growth Potential Reinforce Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on DVAX stock, giving a Buy rating yesterday....

3M ago

DVAX

Dynavax Technologies Reports Strong Q1 2025 Results

Dynavax Technologies ( ($DVAX) ) has released its Q1 earnings. Here is a breakdown of the information Dynavax...

3M ago

DVAX

DVAX FAQ

What was Dynavax Technologies’s price range in the past 12 months?

Dynavax Technologies lowest stock price was $9.22 and its highest was $14.63 in the past 12 months.

What is Dynavax Technologies’s market cap?

Dynavax Technologies’s market cap is $1.34B.

When is Dynavax Technologies’s upcoming earnings report date?

Dynavax Technologies’s upcoming earnings report date is Oct 30, 2025 which is in 83 days.

How were Dynavax Technologies’s earnings last quarter?

Dynavax Technologies released its earnings results on Aug 07, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.105 by $0.035.

Is Dynavax Technologies overvalued?

According to Wall Street analysts Dynavax Technologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dynavax Technologies pay dividends?

Dynavax Technologies does not currently pay dividends.

What is Dynavax Technologies’s EPS estimate?

Dynavax Technologies’s EPS estimate is 0.15.

How many shares outstanding does Dynavax Technologies have?

Dynavax Technologies has 120,080,650 shares outstanding.

What happened to Dynavax Technologies’s price movement after its last earnings report?

Dynavax Technologies reported an EPS of $0.14 in its last earnings report, beating expectations of $0.105. Following the earnings report the stock price went down -10.989%.

Which hedge fund is a major shareholder of Dynavax Technologies?

Currently, no hedge funds are holding shares in DVAX

Dynavax Stock Smart Score

Underperform

Fundamentals

Return on Equity

-10.45%

Trailing 12-Months

Asset Growth

-4.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Dynavax (DVAX) Earnings & Revenues

Historic Earnings Reports

DVAX Company Deck

DVAX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Dynavax demonstrated strong financial performance with record revenue and market share growth for HEPLISAV-B, alongside meaningful pipeline advancements and new programs. However, financial challenges such as a significant allowance for doubtful accounts and a substantial GAAP net loss due to debt refinancing impacted the quarter. Despite these challenges, the overall outlook remains positive with expectations of achieving the upper half of revenue guidance and strong EBITDA growth.View all DVAX earnings summaries

DVAX Stock 12 Month Forecast

Average Price Target

$31.00

▲(178.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","14":"$14","20":"$20","26":"$26","32":"$32"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14,20,26,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.86,12.409230769230769,13.958461538461538,15.507692307692306,17.056923076923077,18.606153846153845,20.155384615384612,21.704615384615384,23.253846153846155,24.803076923076922,26.35230769230769,27.90153846153846,29.45076923076923,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.86,12.409230769230769,13.958461538461538,15.507692307692306,17.056923076923077,18.606153846153845,20.155384615384612,21.704615384615384,23.253846153846155,24.803076923076922,26.35230769230769,27.90153846153846,29.45076923076923,{"y":31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.86,12.409230769230769,13.958461538461538,15.507692307692306,17.056923076923077,18.606153846153845,20.155384615384612,21.704615384615384,23.253846153846155,24.803076923076922,26.35230769230769,27.90153846153846,29.45076923076923,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.68,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >